蛋白酶体β亚基4型对人肝癌SMMC7721细胞增殖存活的影响

陆谦; 程欣; 夏振国; 陈钟

doi:10.3969/j.issn.1001-5256.2020.03.024

蛋白酶体β亚基4型对人肝癌SMMC7721细胞增殖存活的影响

DOI: 10.3969/j.issn.1001-5256.2020.03.024

1. 南通大学附属医院肝胆外科
2. 南通市通州区人民医院普外科

基金项目:

国家自然科学基金(81070360)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 854
- HTML全文浏览量: 29
- PDF下载量: 199
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-06
- 出版日期: 2020-03-20

Effect of proteasome subunit beta type 4 on the proliferation and viability of human liver cancer SMMC7721 cells

Department of Hepatobiliary Surgery,Affiliated Hospital of Nantong University

Research funding:

摘要

摘要: 目的旨在探讨蛋白酶体β亚基4型（PSMB4）对人肝癌SMMC7721细胞增殖存活的影响及其可能的机制。方法利用特异性短发夹RNA（shRNA）技术构建干扰PSMB4表达的SMMC7721实验组细胞;运用MTT、克隆形成实验检测细胞增殖的影响,流式细胞术检测细胞凋亡率的变化,Western Blot检测相关蛋白的表达变化。计量资料两组间比较采用独立样本t检验。结果成功构建了干扰PSMB4表达的SMMC7721实验组细胞（shRNA1:t=22. 67,P <0. 000 1; shRNA2; t=30. 88,P <0. 000 1; shRNA3:t=67. 82,P <0. 000 1）。MTT实验显示第4天（0. 477 0±0. 013 5 vs 0. 323 7±0. 012 7,t=8. 286,P=0. 001 2）、第5天（0. 589 3±0. 008 8 vs 0. 384 7±0. 009 0,t=16. 220,P <0. 000 1）实验组细胞OD490值显著低于对照组。克隆形成实验显示细胞集落数显著减少。流式细胞术显示实验组细胞的早期凋...
- 癌,肝细胞 /
- 蛋白酶体β亚基4型 /
- 细胞增殖 /
- 细胞存活
Abstract: Objective To investigate the effect of proteasome subunit beta type 4( PSMB4) on the proliferation and viability of human liver cancer SMMC7721 cells and its possible mechanisms. Methods The specific short-hairpin RNA( shRNA) technique was used to construct SMMC7721 cells with knockdown expression of PSMB4,and these cells were selected as experimental group. MTT assay and colony-forming assay were used to observe the change in cell proliferation,flow cytometry was used to measure the change in cell apoptosis rate,and Western blot was used to measure the change in the expression of related proteins. The independent samples t-test was used for comparison of continuous data between two groups. Results SMMC7721 cells with knockdown expression of PSMB4 were successfully constructed( shRNA1: t = 22. 67,P < 0. 0001; shRNA2: t = 30. 88,P < 0. 0001; shRNA3: t = 67. 82,P < 0. 0001). The MTT assay showed that the experimental group had a significantly lower OD490 value than the control group on day 4( 0. 4770 ± 0. 0135 vs 0. 3237 ± 0. 0127,t =8. 286,P = 0. 0012) and day 5( 0. 5893 ± 0. 0088 vs 0. 3847 ± 0. 0090,t = 16. 220,P < 0. 0001). The colony-forming assay showed a significant reduction in the number of cell colonies in the experimental group. Flow cytometry showed that compared with the control group,the experimental group had significantly higher early apoptosis rate( 5. 5570% ± 0. 2589% vs 3. 8870% ± 0. 3324%,t = 3. 964,P = 0. 0166),late apoptosis rate( 12. 6300% ± 0. 4198% vs 5. 3100% ± 0. 3062%,t = 14. 080,P = 0. 0001),and total apoptosis rate( 18. 1800% ± 0. 6785%vs 9. 1970% ± 0. 6313%,t = 9. 967,P = 0. 0006),as well as a significant reduction in the protein expression of nuclear factor-kappa B p65( 0. 8015 ±0. 0120 vs 0. 2841 ±0. 0110,t =31. 830,P <0. 0001) and a significant increase in the protein expression of nuclear factor-kappa B inhibitory protein α( 0. 4816 ± 0. 0112 vs 0. 6583 ± 0. 0142,t = 9. 774,P = 0. 0006). Conclusion Knockdown of PSMB4 expression may reduce the proliferation and viability of liver cancer SMMC7721 cells by inhibiting the NF-κB signaling pathway.
- carcinoma,hepatocellular /
- PSMB4 /
- cell proliferation /
- cell survival

HTML全文

参考文献(17)

[1] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.

[2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[3] THOMAS MB,JAFFE D,CHOTI MM,et al. Hepatocellular carcinoma:Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting[J]. J Clin Oncol,2010,28(25):3994-4005.

[4] JANG HH. Regulation of protein degradation by proteasomes in cancer[J]. J Cancer Prev,2018,23(4):153-161.

[5] CHENG YC,TSAI WC,SUNG YC,et al. Interference with PSMB4expression exerts an anti-tumor effect by decreasing the invasion and proliferation of human glioblastoma cells[J]. Cell Physiol Biochem,2018,45(2):819-831.

[6] DANTUMA NP,BOTT LC. The ubiquitin-proteasome system in neurodegenerative diseases:Precipitating factor,yet part of the solution[J]. Front Mol Neurosci,2014,7:70.

[7] MEARINI G,SCHLOSSAREK S,WILLIS MS,et al. The ubiquitin-proteasome system in cardiac dysfunction[J]. Biochim Biophys Acta,2008,1782(12):749-763.

[8] CSIZMAR CM,KIM DH,SACHS Z. The role of the proteasome in AML[J]. Blood Cancer J,2016,6(12):e503.

[9] WANG CY,LI CY,HSU HP,et al. PSMB5 plays a dual role in cancer development and immunosuppression[J]. Am J Cancer Res,2017,7(11):2103-2120.

[10] TAN S,LI H,ZHANG W,et al. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression[J]. Oncogene,2018,37(35):4887-4900.

[11] AUGELLO G,MODICA M,AZZOLINA A,et al. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238(ixazomib)in hepatocellular carcinoma cells[J].Cell Death Dis,2018,9(2):28.

[12] VANDEWYNCKEL YP,COUCKE C,LAUKENS D,et al. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma[J]. Oncotarget,2016,7(23):34988-35000.

[13] LEE KM,LEE J,PARK CS. Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type4[J]. Biochem Biophys Res Commun,2012,427(3):618-622.

[14] WANG H,HE Z,XIA L,et al. PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis[J]. Oncol Rep,2018,40(4):2343-2352.

[15] BU R,HUSSAIN AR,AL-OBAISI KA,et al. Bortezomib inhibits proteasomal degradation of IκBαand induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2014,55(2):415-424.

[16] ZHENG P,GUO H,LI G,et al. PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling[J]. Biochem Biophys Res Commun,2015,458(2):328-333.

[17] LIU R,LU S,DENG Y,et al. PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis[J].Arch Gynecol Obstet,2016,293(6):1297-1307.

施引文献

资源附件(0)

访问统计